Skip Navigation

European Heart Journal 1990 11(Supplement H):4-8; doi:10.1093/eurheartj/11.suppl_H.4
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Assmann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Assmann, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Genes and dyslipoproteinaemias

G. Assmann

Institute of Arteriosclerosis Research, University of Münster Münster, F.R.G.

Address for correspondence: Univ.-Prof. Dr. med Gerd Assmann. Univ Münster, Iristitut für Klinische Chemie und Laboratoriuinsmedizin, Albert-Schweitzer-33, 4400 Münster. F.R.G.

The Prospective Cardiovascular Münster (PROCAM) Study clearly demonstrated that low levels of high density lipoprotein (HDL)-cholesterol are a powerful predictor of subsequent coronary heart disease (CHD) and that both exogenous factors (cigarette smoking, physical inactivity, obesity) and genetic factors (dyslipidaemia, diabetes mellitus) affect serum concentrations of HDL-cholesterol. in case-control studies, the apoprotein (apo) B/apo A-I ratio was found to be more meaningful than the lipoprotein lipid ratio in predicting risk of CHD in a group of young myocardial infarction (MI) survivors. Screening of young (≤45 years) MI survivors did not show an increased prevalence of apo A-I variants compared with controls and newborns, thus apo A-I variants probably do not contribute substantially to low HDL-cholesterol levels and the risk of CHD in the general population. Genetic anomalies causing HDL-cholesterol depletion or apo A-I deficiency probably do not relate to structural anomalies of apo A-I but rather to regulatory anomalies in the production of HDL apolipoproteins or to catabolic or intracellular events that are important in the homeostasis of plasma HDL-cholesterol.

Key Words: PROCAM Study • apolipoproteins • high density lipoproteins • coronary heart disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.